Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics
November 09 2021 - 7:59AM
Business Wire
Accenture (NYSE: ACN) has made a strategic investment, through
Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an
Israel-based developer of genomic analysis and interpretation
software. Geneyx helps improve patient outcomes associated with
hereditary and rare diseases by providing disease-specific,
clinically relevant insights around risk prediction, diagnosis,
prognosis, and treatment for clinical and pharmaceutical
organizations.
Today, many patients receive standardized disease treatments
which are safe and efficient, but not adaptive to an individual’s
unique genetics. Through “New Science". biopharmaceutical companies
have made considerable advances in developing targeted treatments,
including cell and gene therapies, rapidly moving the industry
toward individualized treatments and disease interventions. Yet,
often, this data is siloed at hospitals and research institutions,
hampering our collective understanding of disease biology and the
development of more effective therapeutic options.
Geneyx’s AI-based platform is an example of New Science in
action: it provides biomedical interpretation capabilities that
better enables clinicians and researchers to use the power of
whole-genome sequencing to advance human health. Geneyx technology
leverages AI to improve risk prediction, diagnostic yield,
prognostic prediction, and treatment insights supporting clinical
decision-making and biopharmaceutical research, which help
accelerate the development of targeted and personalized
therapeutics.
Geneyx is also joining Accenture’s network of innovation
partners connected to the INTIENT platform, which enables life
science companies to advance the discovery, development and
commercialization of New Science by connecting deeper intelligence
to actions that improve outcomes. INTIENT helps clients achieve
these goals by leveraging leading cloud-based technologies and an
open partner network to improve collaboration between scientists,
researchers and clinicians.
“We need to improve the treatment-cost equation from the current
ways of operating to new ways of discovering, developing and
commercializing treatments,” said Stuart Henderson, Accenture’s
global lead of the Life Sciences industry group. “Geneyx is driving
a model of collaboration to break down silos in the healthcare
ecosystem to support the capture of the genetic data that will
benefit each patient in their treatment journey.”
David Yizhar, Geneyx CEO and co-founder, added, “Accenture’s
investment and support will enable Geneyx to accelerate the
adoption of our AI-based genomic interpretation technology on a
global scale helping to leverage insights from siloed genetic data
around the world and powering clinical research and pharmaceutical
discovery.”
Geneyx is part of Accenture Ventures’ Project Spotlight, an
engagement and investment program that connects emerging technology
software startups with the Global 2000 to fill strategic innovation
gaps. Project Spotlight offers extensive access to Accenture’s
domain expertise and its enterprise clients, helping startups
harness human creativity and deliver on the promise of their
technology. Geneyx is also the latest addition to the investment
portfolio of Accenture Ventures, which is focused on investing in
companies that create or apply disruptive enterprise
technologies.
“Accenture’s investment in Geneyx reflects our ongoing
commitment to strengthening companies with the potential to
transform their industries,” said Tom Lounibos, managing director
of Accenture Ventures. “Geneyx is well-positioned to make
meaningful impact in clinical genetic data analysis, ultimately
helping more patients in need. We are excited to support them on
this important journey.”
Terms of the investment were not disclosed.
Accenture’s Life Sciences industry group helps pharmaceutical,
biotech, medical technology, distributor and consumer health
companies combine the latest technology with scientific
breakthroughs to revolutionize how medical treatments are
discovered, developed and delivered to patients around the world.
To learn more, visit
https://www.accenture.com/us-en/industries/life-sciences-index.
About Accenture Accenture is a global professional
services company with leading capabilities in digital, cloud and
security. Combining unmatched experience and specialized skills
across more than 40 industries, we offer Strategy and Consulting,
Interactive, Technology and Operations services — all powered by
the world’s largest network of Advanced Technology and Intelligent
Operations centers. Our 624,000 people deliver on the promise of
technology and human ingenuity every day, serving clients in more
than 120 countries. We embrace the power of change to create value
and shared success for our clients, people, shareholders, partners
and communities. Visit us at www.accenture.com.
About Geneyx Geneyx offers a superior NGS data analysis
and interpretation platform, harnessing genetic data to guide
digital insights for rare and germline disorders. Our AI-based
analysis platform streamlines the diagnostics process, from the raw
genetic data to the final clinical report. Geneyx develops unique
technologies and utilizes diverse databases in the interpretation
of WGS (whole-genome sequencing), WES (whole-exome sequencing), and
gene panels. For more information visit To learn more visit
https://geneyx.com.
Copyright ©2021 Accenture. All rights reserved. Accenture and
its logo are registered trademarks of Accenture
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109005593/en/
Marchell Gillis Accenture +1 678 657 7515 (office) +1 404 409
9430 (mobile) marchell.gillis@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Apr 2023 to Apr 2024